SLC35A2 loss-of-function variants affect glycomic signatures, neuronal fate and network dynamics
Brain · 2025
DOI: 10.1093/brain/awaf198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Dulcie Lai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: Neurons, Monosaccharide Transport Proteins, Nerve Net. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
SLC35A2 encodes a uridine diphosphate (UDP)-galactose transporter essential for glycosylation of proteins and galactosylation of lipids and glycosaminoglycans. Germline genetic SLC35A2 variants have been identified in congenital disorders of glycosylation and somatic SLC35A2 variants have been linked to intractable epilepsy associated with malformations of cortical development. However, the functional consequences of these pathogenic variants on brain development and network integrity remain unknown. In this study, we used an isogenic human-induced pluripotent stem cell-derived neuron model to comprehensively interrogate the functional impact of loss-of-function variants in SLC35A2 through the integration of cellular and molecular biology, protein glycosylation analysis, neural network dynamics and single-cell electrophysiology. We show that loss-of-function variants in SLC35A2 result in disrupted glycomic signatures and precocious neurodevelopment, yielding hypoactive, asynchronous neural networks. This aberrant network activity is attributed to an inhibitory/excitatory imbalance as characterization of neural composition revealed preferential differentiation of SLC35A2 loss-of-function variants towards a GABAergic fate. Furthermore, electrophysiological recordings of synaptic activity and gene expression differences suggest network phenotypes are driven by changes occurring at the synapse. Our study is the first to provide mechanistic insight regarding the early development and functional connectivity of SLC35A2 loss-of-function variant harbouring human neurons, providing important groundwork for future exploration of potential therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
- Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
- Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Center for Epilepsy and Neurodevelopmental Disorders, Perelman School of Medicine, University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
ORCID-Profile: Dulcie Lai, Hudson H Freeze, Erin L Heinzen
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
Zitieren
APA
Lai, D., Sosicka, P., Williams, D. J., Bowyer, M. E., Ressler, A. K., Kohrt, S. E., Muron, S. J., Crino, P. B., Freeze, H. H., Boland, M. J., & Heinzen, E. L. (2025). SLC35A2 loss-of-function variants affect glycomic signatures, neuronal fate and network dynamics. Brain. https://doi.org/10.1093/brain/awaf198
Vancouver
Lai D, Sosicka P, Williams DJ, Bowyer ME, Ressler AK, Kohrt SE, et al. SLC35A2 loss-of-function variants affect glycomic signatures, neuronal fate and network dynamics. Brain. 2025. doi:10.1093/brain/awaf198
BibTeX
@article{Lai2025,
author = {Lai, Dulcie and Sosicka, Paulina and Williams, Damian J and Bowyer, MaryAnn E and Ressler, Andrew K and Kohrt, Sarah E and Muron, Savannah J and Crino, Peter B and Freeze, Hudson H and Boland, Michael J and Heinzen, Erin L},
title = {SLC35A2 loss-of-function variants affect glycomic signatures, neuronal fate and network dynamics},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awaf198}
}
EUVIMED